Regeneron Follows REGEN-COV Revenue Success With Impressive PD-1 Data

Libtayo Showed Efficacy With Chemo In 1L NSCLC

 
• By Jessica Merrill
Regeneron
Regeneron had a strong second quarter. • Source: Alamy

More from Earnings

More from Business